Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986315 + Nivolumab + Chemo in NSCLC
NCT06094296Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of BMS-986315 in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events (AEs), Number of Participants With Treatment Related Adverse Events (TRAEs) and 5 more. Started Nov 2023; status: terminated.
02
Drugs
BMS-986315
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06094296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094296.